Search

Your search keyword '"Hansson, Markus"' showing total 615 results

Search Constraints

Start Over You searched for: Author "Hansson, Markus" Remove constraint Author: "Hansson, Markus"
615 results on '"Hansson, Markus"'

Search Results

1. Deciphering the genetics and mechanisms of predisposition to multiple myeloma

3. Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group

8. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

9. Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial

10. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

15. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

16. Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden

17. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

20. Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk

21. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

24. Germline variants at SOHLH2 influence multiple myeloma risk

25. P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study

27. Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

29. P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

30. P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY

31. P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

32. Direct evidence for a polygenic etiology in familial multiple myeloma

33. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

35. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

37. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

38. Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

39. Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes

42. Use of linked nordic registries for population studies in hematologic cancers : the case of multiple myeloma

43. Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients

44. Use of Linked Nordic Registries for Population Studies in Hematologic Cancers: The Case of Multiple Myeloma

46. Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo

47. Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody (R)-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

50. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Catalog

Books, media, physical & digital resources